Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells?
暂无分享,去创建一个
D. Heymann | F. Redini | K. Mori | K. Ando
[1] D. Heymann,et al. Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. , 2007, Oncology reports.
[2] B. Pitard,et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.
[3] B. Le Goff,et al. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. , 2007, Bone.
[4] B. Le Goff,et al. Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B , 2007, The Journal of pathology.
[5] M. Dimopoulos,et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton , 2007, Acta oncologica.
[6] M. Padrines,et al. OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. , 2006, Bone.
[7] E. Steliarova-Foucher,et al. Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. , 2006, European journal of cancer.
[8] A. Potti,et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation , 2006, Cancer.
[9] L. Pham,et al. Nuclear Localization in the Biology of the CD40 Receptor in Normal and Neoplastic Human B Lymphocytes* , 2006, Journal of Biological Chemistry.
[10] S. M. Sims,et al. Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.
[11] E. Schwarz,et al. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone , 2005, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[12] C. Herzog. Overview of Sarcomas in the Adolescent and Young Adult Population , 2005, Journal of pediatric hematology/oncology.
[13] E. Kleinerman,et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Vessella,et al. Osteoprotegerin in prostate cancer bone metastasis. , 2005, Cancer research.
[15] S. Théoleyre,et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.
[16] G. Roodman. Mechanisms of bone metastasis. , 2004, Discovery medicine.
[17] W. Dougall,et al. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. , 2003, Cancer research.
[18] M. Tomasson,et al. Platelet and osteoclast β3 integrins are critical for bone metastasis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[19] Yanan Li,et al. Expression and function of TNF-family proteins and receptors in human osteoblasts. , 2003, Bone.
[20] M. Weitzmann,et al. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts , 2003, Journal of cellular biochemistry.
[21] G. Mundy,et al. Mechanisms of osteolytic bone metastases in breast carcinoma , 2003, Cancer.
[22] R. Berezney,et al. Integrative nuclear FGFR1 signaling (INFS) pathway mediates activation of the tyrosine hydroxylase gene by angiotensin II, depolarization and protein kinase C , 2002, Journal of neurochemistry.
[23] K. Makino,et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.
[24] A. Mizokami,et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. , 2001, The Journal of clinical investigation.
[25] D. Goltzman. Osteolysis and cancer. , 2001, The Journal of clinical investigation.
[26] R. Vessella,et al. Osteoprotegerin and rank ligand expression in prostate cancer. , 2001, Urology.
[27] D. Lacey,et al. The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.
[28] T. Guise. Molecular mechanisms of osteolytic bone metastases , 2000, Cancer.
[29] P. Hersey,et al. Differential Localization and Regulation of Death and Decoy Receptors for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Human Melanoma Cells1 , 2000, The Journal of Immunology.
[30] M. Zheng,et al. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. , 2000, The American journal of pathology.
[31] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.
[32] H. Yasuda,et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.
[33] W. Min,et al. The N-terminal domains target TNF receptor-associated factor-2 to the nucleus and display transcriptional regulatory activity. , 1998, Journal of immunology.
[34] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[35] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[36] R. Steinman,et al. TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.
[37] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[38] R. Coleman. Skeletal complications of malignancy , 1997, Cancer.
[39] F. Orr,et al. Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. , 1997, European journal of cancer.
[40] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[41] R. Kannagi,et al. Alteration of integrins by heparin-binding EGF-like growth factor in human breast cancer cells. , 1996, Oncology.
[42] H. Asaoku,et al. Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. , 1989, Blood.
[43] R. Baggs,et al. A murine model of experimental metastasis to bone and bone marrow. , 1988, Cancer research.
[44] S Paget,et al. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .
[45] W. Dougall,et al. RANKL acts directly on RANK‐expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes , 2008, The Prostate.
[46] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[47] P. Kostenuik,et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis , 2007, Clinical & Experimental Metastasis.
[48] D. Heymann,et al. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. , 2006, International journal of oncology.
[49] M. Hansen,et al. Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] B. Strahl,et al. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. , 2003, Nature.
[51] M. Tsurudome,et al. Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. , 2002, International immunopharmacology.
[52] Taylor Murray,et al. Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.